Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 7/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | FER | P16591 | 1/20 | 0.52 |
| ▸ | LTK | P29376 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9094667 | 0.81 | ALOX5 (0.50) | ALOX5PDGFRATDP1MEN1KMT2A | |
| Phenoxazine SCHEMBL29355714 | 0.79 | ALOX5 (1.00) | ALOX5TDP1MEN1KMT2AMAPT | |
| Phenoxazine SCHEMBL6310178 | 0.79 | ALOX5 (1.00) | ALOX5TDP1MEN1KMT2AMAPT | |
| Phenoxazine SCHEMBL28844098 | 0.79 | ALOX5 (1.00) | ALOX5TDP1MEN1KMT2AMAPT | |
| Phenoxazine SCHEMBL7862 | 0.79 | ALOX5 (1.00) | ALOX5TDP1MEN1KMT2AMAPT | |
| SCHEMBL31599584 | 0.78 | ALOX5 (0.70) | ALOX5PDGFRAFERLTKCDK8 | |
| SCHEMBL380110 | 0.78 | ALOX5 (0.61) | ALOX5PDGFRAFERLTKCDK8 | |
| SCHEMBL5739379 | 0.77 | MAPT (0.52) | ALOX5TDP1MEN1KMT2AMAPT | |
| SCHEMBL5937361 | 0.77 | CYP1A2 (0.61) | ALOX5ALOX15MEN1KMT2ATYMS | |
| Phenoxazine SCHEMBL25275195 | 0.77 | ALOX5 (0.94) | ALOX5TDP1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019161781-A1 | RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USAGE THEREOF | 北京泰德制药股份有限公司 | 2019-08-29 | — | — | WO | disclosed |
| US-20140221468-A1 | Compounds that Modulate Store Operated Calcium Channels | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-08-07 | — | — | US | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| WO-2012079020-A2 | COMPOUNDS THAT MODULATE STORE OPERATED CALCIUM CHANNELS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-06-14 | — | — | WO | disclosed |
| US-8158623-B2 | Heptacyclic compounds and the pharmaceutical uses thereof for preventing and treating diabetes and metabolic syndrome | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES (CN) | 2012-04-17 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCE | 2010-07-08 | — | — | US | disclosed |
| EP-2199295-A1 | COMPOUNDS WITH 7-MEMBER CYCLE AND THE PHARMACEUTICAL USE THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLISM SYNDROME | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2010-06-23 | — | — | EP | disclosed |
| US-5104980-A | CHROMOGENIC DIBENZOXAZEPINONE AND DIBENZOTHIAZEPINONE ENZYME SUBSTRATES | MILES INC. (US) | 1992-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | ALOX5 2621/4885PDGFRA 4656/4885FER 4157/4885 |
| US-20140221468-A1 | Compounds that Modulate Store Operated Calcium Channels | CACNA1C, SARAF, CACNA1G | ALOX5 473/4885PDGFRA 2277/4885FER 4445/4885 |
| US-20100173905-A1 | HEPTACYCLIC COMPOUNDS AND THE PHARMACEUTICAL USES THEREOF FOR PREVENTING AND TREATING DIABETES AND METABOLIC SYNDROME | GPR119, CYP11B1, HSD11B1 | ALOX5 73/4885PDGFRA 3886/4885FER 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.